Mastodawn

Q&A: Families shouldn’t have to coordinate Sweden’s rare disease care https://www.politico.eu/sponsored-content/families-shouldnt-have-to-coordinate-swedens-rare-disease-care/?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS_Syndication #Advancedtherapies #Regions/Cohesion #Accountability #Communications #Healthsystems #Rarediseases #Transparency #Governance #Healthcare #Regulation #HealthCare #Hospitals #Medicines #Stability #Advocacy #Patients #Research #Services #Borders #Bridges #digital

Q&A: Families shouldn’t have to coordinate Sweden’s rare disease care

A Q&A with Zozan Sewger Kvist, CEO of rare disease competence center Ågrenska, on stalled reform, uneven access to care in Europe and the limits of regulation.

POLITICO

Dr. Marie McNeely Aug 8, 2024

Dysfunction in the homeostasis of iron and other elements likely contributes to the development of Parkinson's disease (PD), and Dr. Paul Lingor is working to identify patterns of bioelements in CSF that could be used as biomarkers. He is also studying tear fluid as a potential biomarker source and is involved in studying PD therapies, including the drug Fasudil as well as combinations of advanced therapies for people with later-stage PD. Learn more about his work in our latest podcast episode!

https://www.michaeljfox.org/podcast/episode-20-studying-csf-element-profiles-and-tear-fluid-potential-biomarkers-and-novel-and

#Parkinsons #ParkinsonsDisease #ParkinsonsResearch #Neuroscience #Neurology #Biomarkers #Biomarker #Diagnostics #ClinicalTrials #AdvancedTherapies #Research #MJFF

Episode 20: Studying CSF Element Profiles and Tear Fluid as Potential Biomarkers, and Novel and Combined Therapies for PD with Paul Lingor

Dr. Paul Lingor discusses his work in this area to identify patterns of bioelements in CSF that could serve as Parkinson's disease biomarkers.

The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease

Dr Marguerite Evans-Galea AM Jan 7, 2024

NSW Health, Australia, has set a national benchmark for standardising the preparation of pharmaceuticals and advanced therapeutic products with a new Policy Directive that outlines new and updated state-wide approaches.

Learn more about the Directive & author Kerry Watts: https://www.medicalresearch.nsw.gov.au/future-proofing-nsw-health-production-ofpharmaceuticals-and-advanced-therapeutics/ #AdvancedTherapies #CellTherapies #GeneTherapies

Manjunatha Dec 8, 2023

NexCAR19 CAR T Cell Therapy: Tailoring the Approach to B-Cell Lymphoma Treatment

NexCAR19 CAR T cell therapy is a groundbreaking treatment for B-cell lymphomas that has recently received approval in India. This innovative therapy harnesses the power of the patient's own immune system to fight cancer cells. #NexCAR19 #oncologyhealthcareindia #carttherapy #india #immunoactindia #lymphoma #advancedtherapies

https://mindfulcells.com/2023/12/nexcar19-car-t-cell-therapy-tailoring-the-approach/

#science #scientist #biology #mentalhealth

What Makes NexCAR19 CAR T Cell Therapy Unique? Find Out Here

The power of technology: NexCAR19 CAR T Cell therapy, approved by CDSCO in India. Discover its influence on CD4+ and CD8+ T cell subsets. #CARTCellTherapy #NexCAR19 #NexCAR19CARTCelltherapy #OncologyhealthcareIndia #Regenerativehealtheducation #ActalyCel™ #Actalycabtageneautoleucel

Mindfulcells